Studies have shown that NEP inhibitors can cause biochemical and pathological deposition of Aβ1–4229, and in vitro experiments show that NEP can rapidly degrade Aβ1–40 and Aβ1–4230, while exogenous supplementation of NEP can reduce the deposition of Aβ in AD transgenic mice31. This evidence concerns the gene MME and Alzheimer disease.